implicity
Request A Demo

Delphine LEFEBVRE

Implicity Hosts US Research Competition for Free Access to Advanced AI-powered Cardiac Remote Monitoring Platform

Implicity Hosts US Research Competition for Free Access to Advanced AI-powered Cardiac Remote Monitoring Platform

Delphine LEFEBVRE / March 11, 2022

Implicity Hosts US Research Competition for Free Access to Advanced AI-powered Cardiac Remote Monitoring Platform Clinical and academic researchers can apply for one of three spots for free access to cardiac remote monitoring and ILR ECG Analyzer to support CRM research Cambridge, Mass., March 10th, 2022 – Implicity, a leader in AI-powered remote patient monitoring and cardiac data management solutions, today announced an invitation for US-based researchers who are looking to conduct a study in the field of Cardiac Rhythm Management to apply for free access to Implicity’s cardiac remote monitoring software, including the ILR ECG Analyzer* & Advanced Research Tool. This is an opportunity for investigators to use highly-intelligent cardiac remote care & research solutions to support their studies for a minimum of one year, with support from Implicity’s team of data scientists and engineers. “Research is at the heart of what we do at Implicity. Our solution is already the official remote monitoring platform of one of the largest research consortiums in Europe, our goal now is to support academic medical centers, physicians, and researchers in the US as we look to improve the treatment and diagnosis of cardiovascular diseases. We are excited to host this unique research competition, provide study support through our device-agnostic platform, and learn of the findings from these studies,” said Dr. Arnaud Rosier, CEO, and founder of Implicity. Cardiac remote monitoring has already been shown to reduce the number of unnecessary emergency department visits and improve the time to diagnose clinical events. As the adoption of RM continues to grow, more studies will be needed to measure the ongoing impact of emerging technologies and new applications. From managing patient data content forms to organizing cross-device data, the Implicity platform is an effective tool that researchers can use to drive more efficient operations while also enabling scale. Implicity’s research competition is open to physicians, medical interns, physician groups, academic facilities, PhDs, PhD students or other allied health professionals based in the United States, leading studies that involve remote monitoring data from cardiac implantable electronic devices (CIEDs), ILR ECG analysis, or other areas related to cardiac remote monitoring. The deadline to apply is Tuesday May 10th, 2022. A panel of industry judges will make decisions shortly thereafter – the panel includes Prof. Jagmeet Singh (Boston, MA), Prof. Niraj Varma (Cleveland, OH/London, ENG) and Dr. Suneet Mittal (Paramus, NJ/New York City, NY). Winners receive free access to Implicity’s AI-powered Cardiac Remote Monitoring platform and features, including the ILR ECG Analyzer and the Advanced Research Tool module, for a minimum of 12 months. For application instructions and proposal requirements, visit: https://implicity.com/landing-page/research_contest/ or reach out directly to Implicity at researchcontest@implicity.com About Implicity Implicity provides an AI-powered remote monitoring and research platform used by Independent Diagnostic Testing Facilities and cardiac electrophysiology centers worldwide to deliver advanced high-quality care for their patients with connected CIEDs. On this platform, Implicity aggregates, normalizes and standardizes data from any implantable cardiac device across all manufacturers. Furthermore, Implicity carries out R&D on AI-based algorithms aiming at improving patient care and serving the future of preventive medicine. Implicity is the first private company authorized to access the Health Data Hub**, one of largest databases of patients with heart diseases in the world, supporting the development of its ground-breaking AI solutions. Implicity covers 70,000 patients in over 100 medical facilities across Europe and the United States. * FDA cleared Class II medical device and CE marked Class I (under MDD) medical device, see the instructions for use for more information. ** Health Data Hub is a health data platform put in place by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.

September is the #AFib Awareness Month

September is the #AFib Awareness Month

Delphine LEFEBVRE / September 29, 2021

September is the #AFib Awareness Month What is Atrial Fibrillation? Atrial fibrillation (AF) is the most frequent cardiac arrhythmia. AF is a significant burden to healthcare professionals and society, with an increased risk of stroke and embolism. Its incidence varies with age, from 1.7% for the youngest to 23.4% for the oldest. Moreover, AF also impacts patients’ mortality, increasing with age. The use of a cardiac implantable electronic device (CIED) is familiar, and its relationship to AF has been widely described in the literature. It has been demonstrated that patients implanted with a dual-chamber pacemaker experienced AF in 75% of the cases, and 69% of the patients had AF detected by the pacemaker despite being asymptomatic. Insertable cardiac monitors (ICMs) are a solution to record a patient’s electrocardiogram for up to several years. ICMs automatically record abnormal rhythmic episodes, such as bradycardias, tachycardias, and AF. CIEDs transmit the abnormal events by remote monitoring to the manufacturer, then transfer them to the physician. This amount of information can impact the workflow of the healthcare providers in charge of analyzing them. The main limitation is the number of false positive diagnoses classified as an AF event when it was just an artifact or noise. Remote monitoring (RM) is recommended to reduce the number of in-office follow-ups for patients with pacemakers who have difficulties attending in-office visits. RM is also utilized to detect the progression of clinical AF, monitor the atrial high-rate episodes and subclinical AF burden, and see changes in underlying clinical conditions. Implicity is committed to improving efficient and early AF detection via RM to improve patient care. Implicity’s latest science shows the performance of a novel algorithm to reduce by 79% the false positive rate of Medtronic ICM devices (HRS 2021). Moreover, Implicity developed a new AI-based algorithm allowing the reduction of false positive AF detection by 72% (ESC 2021). Implicity is involved in developing new AI solutions that save healthcare professionals time and ease the workload in patient follow-up. Jean-Luc Bonnet, Ph.D., Head of Clinical Affairs, Implicity

The Smarter Way to Monitor Every Heart.

Smarter monitoring / Cleaner alerts / Faster decisions

Request a Demo